Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Evidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which different cancer cells contribute to propagating malignancies in patients remains unexplored. In low- to intermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Woll, P, Kjällquist, U, Chowdhury, O, Doolittle, H, Wedge, D, Thongjuea, S, Erlandsson, R, Ngara, M, Anderson, K, Deng, Q, Mead, A, Stenson, L, Giustacchini, A, Duarte, S, Giannoulatou, E, Taylor, S, Karimi, M, Scharenberg, C, Mortera-Blanco, T, Macaulay, I, Clark, SA, Dybedal, I, Josefsen, D, Fenaux, P, Hokland, P, Holm, MS, Cazzola, M, Malcovati, L, Tauro, S, Bowen, D, Boultwood, J, Pellagatti, A, Pimanda, J, Unnikrishnan, A, Vyas, P, Göhring, G, Schlegelberger, B, Tobiasson, M, Kvalheim, G, Constantinescu, SN, Nerlov, C, Nilsson, L, Campbell, P, Sandberg, R, Papaemmanuil, E, Hellström-Lindberg, E, Linnarsson, S, Jacobsen, S
Formato:	Journal article
Idioma:	English
Publicado em:	Cell Press 2014

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Registros relacionados